Best Industrial Disributor Stocks To Invest In 2015

Best Industrial Disributor Stocks To Invest In 2015: Seattle Genetics Inc.(SGEN)

Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

Advisors' Opinion:

• [By Roberto Pedone]

  One biotechnology player that insiders are snapping up a huge amount of stock in here is Seattle Genetics (SGEN), which develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. Insiders are buying this stock into huge strength, since shares are up sharply by 72% so far in 2013.

  Seattle Genetics has a market cap of $4.9 billion and an enterprise value of $4.5 billion. This stock trades at a premium valuation, with a price-to-sales of 19.09 and a price-to-book of 21.65. Its estimated growth rate for ! this year is -37%, and for next year it's pegged at -6.3%. This is a cash-rich company, since the total cash position on its balance sheet is $373.85 million and its total debt is zero.

  A director just bought 1,005,901 shares, or about $43.44 million worth of stock, at $42.31 to $43.98 per share.

  From a technical perspective, SGEN is currently trending above its 200-day moving average and just below its 50-day moving average, which is neutral trendwise. This stock has been downtrending over the last few weeks, with shares dropping from its high of $45.37 to its intraday low of $39.85 a share. During that move, shares of SGEN have been consistently making lower highs and lower lows, which is bearish technical price action.

  If you're bullish on SGEN, then I would look for long-biased trades as long as this stock is trending above its 200-day of $38.40 or above more near-term support at $36.79 and then once it takes out its 50-day at $41.02 a share with high volume. Look for a sustained move or close above that level with volume that hits near or above its three-month average volume of 856,995 shares. If we get that move soon, then SGEN will set up to re-test or possibly take out its next major overhead resistance levels at $45.37 $46.48 a share. Any high-volume move above those levels will then give SGEN a chance to tag its 52-week high at $49.23 a share.

• [By Brian Orelli]

  It's certainly in the FDA's right to ask outside experts for their opinion; I would argue it's not all that surprising even if the FDA is leaning strongly toward approving the drug. There are plenty of cases --Seattle Genetics' (NASDAQ: SGEN  ) Adcetris,for example--where the FDA called a meeting only to gush all over the drug. The drug got a unanimous positive recommendation from the panel and was approved early by the FDA.

• [By Sean Williams]

  These might not be household names in the U.S., but they do brandish global licensing partnerships with compan! ies that ! might be more familiar to you. Takeda, for example, has licensing agreements in place with Orexigen Therapeutics (NASDAQ: OREX  ) , which recently filed a New Drug Application for its chronic weight management (i.e., anti-obesity) pill, Contrave, in the U.S. Takeda owns the right to Contrave outside of North America. In addition, Takeda is a collaborative partner of antibody-drug conjugate developer Seattle Genetics (NASDAQ: SGEN  ) with regard to FDA-approved Hodgkin lymphoma drug Adcetris.

• [By Rich Bieglmeier]

  [Related -Seattle Genetics, Inc. (SGEN), Takeda Report Encouraging Data From ADCETRIS Study]

  Let's take a look at what $2 billion in ADCETRIS sales could mean for the stock price and where SGEN shares would need to trade to become a low-end large cap stock.

source from Top Penny Stocks For 2015:http://www.seekpennystocks.com/best-industrial-disributor-stocks-to-invest-in-2015-3.html